88336-99-6

Usage

Uses

Used in Fragrance and Flavoring Industry:
METHYL 15-PHENYLPENTADECANOATE is used as a key ingredient in the production of fragrances and flavorings due to its appealing scent and taste, enhancing the overall sensory experience of various products.
Used in Cosmetics Manufacturing:
In the cosmetics industry, METHYL 15-PHENYLPENTADECANOATE serves as a valuable component, contributing to the formulation of perfumes, lotions, and other beauty products. Its stability and low volatility ensure a consistent performance and longevity in these products.
Used as an Industrial Solvent:
METHYL 15-PHENYLPENTADECANOATE is also utilized as a solvent in various industrial processes, where its chemical properties prove advantageous for specific applications, such as in the production of certain types of coatings or adhesives.

InChI:InChI=1/C22H36O2/c1-24-22(23)20-16-11-9-7-5-3-2-4-6-8-10-13-17-21-18-14-12-15-19-21/h12,14-15,18-19H,2-11,13,16-17,20H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 40228-93-1 ω-phenyl pentadecanoic acid 
• 3344-70-5 1,12-dibromododecane 
• 109-29-5 15-hexadecanolide 
• 104-15-4 toluene-4-sulfonic acid 
• 536-74-3 phenylacetylene 
• 104827-29-4 15-Phenyl-pentadecanenitrile 
• 104827-28-3 (14-Bromo-tetradecyl)-benzene 
• 104827-27-2 14-bromo-1-phenyl-tetradec-1-yne 

Downstream Products

• 88337-00-2 methyl 15-(p-iodophenyl)pentadecanoate 
• 80479-93-2 15-(p-iodophenyl)pentadecanoic acid 

Relevant academic research and scientific papers

HPYY(1-36) Having a Beta-Homoarginine Substitution at Position 35

The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Methode de synthese d'acides gras marques substitues ou non en α et en β

2-Propyn-1-ol and the dibromides Br(CH2)nBr (n = 10-12) have been used as starting materials for the synthesis of α- and β-methyl-branched fatty acids (C16) labeled with 123I at the ω-position.The methyl groups are introduced through the use of the lithium salt of either propanoic or isobutyric acid.The synthesis of *IC6H5(CH2)14COOH and *IC6H5(CH2)12CH(CH3)CH2COOH have been achieved in the same way starting from phenylacetylene.In each case, the radioactive iodine atom is introduced by an I/*I exchange reaction.

Synthesis and Evaluation of Radioiodinated Terminal p-Iodophenyl-Substituted α- and β-Methyl-Branched Fatty Acids

Methods have been developed for the preparation of terminal p-iodophenyl-substituted α- and β-methyl-branched long-chain fatty acids.The syntheses and physical properties of 14-(p-iodophenyl)-2(RS)-methyltetradecanoic acid and 15-(p-iodophenyl)-3(RS)-methylpentadecanoic acid are described.The radioiodinated agents are of interest as a result of the expected pronounced uptake and prolonged myocardial retention that may result from the inhibition of fatty acid metabolism.Tissue distribution studies in rats with 14-(p-iodophenyl)-2(RS)-methyltetradecanoic acidand 15-(p-iodophenyl)-3(RS)-methylpentadecanoic acid show significant heart uptake and prolonged retention accompanied by low in vivo deiodination and high blood levels.A comparison of the heart uptake of the radioiodinated methyl-branched fatty acids and their unbranched analogues has demonstrated a greater myocardial retention of the methyl-branched fatty acids than the unbranched analogues.These results suggest that the mechanism of myocardial retention results from steric or chemical inhibition of the metabolism of these fatty acids by the presence of the methyl group.